T cells have the capacity to eradicate diseased cells, but tumours present considerable
challenges that render T cells ineffectual. Cancer cells often make themselves …

Harnessing the power of the immune system to recognize and eliminate cancer cells is a
longtime exploration. In the past decade, monoclonal antibody (mAb)-based immune …

SLAMF7 is under intense investigation as a target for immunotherapy in multiple myeloma.
In this study, we redirected the specificity of T cells to SLAMF7 through expression of a …

Autologous chimeric antigen receptor-modified (CAR) T cells with specificity for CD19
showed potent antitumor efficacy in clinical trials against relapsed and refractory B-cell acute …

Abstract Cluster of differentiation 38 (CD38) is a multifunctional extracellular enzyme on the
cell surface with NADase and cyclase activities. CD38 is not only expressed in human …

Recent clinical success has underscored the potential for immunotherapy based on the
adoptive cell transfer (ACT) of engineered T lymphocytes to mediate dramatic, potent, and …

Non-Hodgkin's lymphoma (NHL) is a cancer that starts in the lymphatic system. In NHL, the
important part of the immune system, a type of white blood cells called lymphocytes become …

The robust and stable expression of CD38 in T‐cell acute lymphoblastic leukemia (T‐ALL)
blasts makes CD38 chimeric antigen receptor (CAR)‐T/natural killer (NK) a potential therapy …

The use of chimeric antigen receptor (CAR)–modified T cells as a therapy for hematologic
malignancies and solid tumors is becoming more widespread. However, the infusion of a T …

CD19-targeted chimeric antigen receptor (CAR) T cells are currently being tested in the
clinic with very promising outcomes. However, limitations to CAR T cell therapy exist. These …